- Home
- BCTX vs ICAD Comparison
BCTX vs ICAD Comparison
Compare BCTX & ICAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- ICAD
- Stock Information
- Founded
- BCTX 2014
- ICAD 1984
- Country
- BCTX Canada
- ICAD United States
- Employees
- BCTX N/A
- ICAD N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- ICAD Medical/Dental Instruments
- Sector
- BCTX Health Care
- ICAD Health Care
- Exchange
- BCTX Nasdaq
- ICAD Nasdaq
- Market Cap
- BCTX 34.6M
- ICAD 40.8M
- IPO Year
- BCTX N/A
- ICAD 1986
- Fundamental
- Price
- BCTX $0.41
- ICAD $2.41
- Analyst Decision
- BCTX Strong Buy
- ICAD
- Analyst Count
- BCTX 1
- ICAD 0
- Target Price
- BCTX $15.00
- ICAD N/A
- AVG Volume (30 Days)
- BCTX 977.6K
- ICAD 235.8K
- Earning Date
- BCTX 03-17-2025
- ICAD 03-11-2025
- Dividend Yield
- BCTX N/A
- ICAD N/A
- EPS Growth
- BCTX N/A
- ICAD N/A
- EPS
- BCTX N/A
- ICAD N/A
- Revenue
- BCTX N/A
- ICAD $18,940,000.00
- Revenue This Year
- BCTX N/A
- ICAD $10.15
- Revenue Next Year
- BCTX N/A
- ICAD $3.75
- P/E Ratio
- BCTX N/A
- ICAD N/A
- Revenue Growth
- BCTX N/A
- ICAD 10.03
- 52 Week Low
- BCTX $0.37
- ICAD $1.18
- 52 Week High
- BCTX $4.37
- ICAD $2.65
- Technical
- Relative Strength Index (RSI)
- BCTX 36.36
- ICAD 70.67
- Support Level
- BCTX $0.38
- ICAD $1.81
- Resistance Level
- BCTX $0.42
- ICAD $2.04
- Average True Range (ATR)
- BCTX 0.05
- ICAD 0.16
- MACD
- BCTX 0.00
- ICAD 0.03
- Stochastic Oscillator
- BCTX 12.86
- ICAD 80.49
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.